CA2029883A1 - Column packing for high specific gravity liporotein and/or hdl cholesterol fractionation measurement - Google Patents
Column packing for high specific gravity liporotein and/or hdl cholesterol fractionation measurementInfo
- Publication number
- CA2029883A1 CA2029883A1 CA002029883A CA2029883A CA2029883A1 CA 2029883 A1 CA2029883 A1 CA 2029883A1 CA 002029883 A CA002029883 A CA 002029883A CA 2029883 A CA2029883 A CA 2029883A CA 2029883 A1 CA2029883 A1 CA 2029883A1
- Authority
- CA
- Canada
- Prior art keywords
- specific gravity
- column packing
- high specific
- measurement
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
ABSTRACT
A column packing for a high specific gravity lipoprotein and/or HDL cholesterol fractionation measurement and comprising a porous calcium compound as the constituent thereof.
A column packing for a high specific gravity lipoprotein and/or HDL cholesterol fractionation measurement and comprising a porous calcium compound as the constituent thereof.
Description
TUK.ADV 7871~PCT/,~
- 1 2~29~83 DESCRIPTION
TITLE OF THE INVENTION
Column Packing for High Specific Gravity Lipoprotein and/or HDL Cholesterol Fractionation Measurement TECHNICAL FIELD
This invention relates to a column packing (or filler~ for high specific gravity lipoprotein and~or HDL
cholesterol fractionation measurement.
BACKGROUND ART
The recent trend in Japan toward the adoption of a western diet has led to the opening of a large number of supermarkets after midnight supplying a vast diYersity of food, etc. Also, a gourmet boom has led to an intake of foods having a higher calory content. Accordingly, the growth of diseases caused by over-eating, etc., such as diabetes, hyperlipemia or fatty liver, has increased, and accordingl~, it appears to be time to cut down on the intake of many foods. On the other hand, from a global point of view, in many developping countries and countries in a state of war, due to an extremely poor hygienic environment or to a severe lack of food, there are many people who are suffering from an irreversible malnutrition. The therapy of the diseases due to nutritional disorders caused by such an excessive or insufficient nutrition mer~ly by negative methods, such as a nutritional limitation or supplementation, etc., does not always give good results, and accordingly, in most practical clinics, a large number of therapeutical methods, including a drug therapy such as the hyperlipemia therapeutic method, the plasma exchange-plasma separation method, and the central vein nutrition method, etc., have been investigated.
Also, simultaneously with the establishment o~ the therapeutical method, due to the progress made in 3s clinical tests in the diagnosis field, such as the 2029~83 advent of the en~ymatic method and development of a biological automatic analyzer, the tested number of lipids in blood has increased, and further, a precise diagnosis, such as an apoprotein measurement, is now possible, and the significance thereof in clinical tests is increasing. The measurement of high specific gravity lipoprotein and/or HDL cholesterol (HDL-C) fractions has become substantially routine among the series of lipid tests. This is because it is widely known that there is a negative correlation between the HDL-C concentration and the onset ratio of arterioscrelotic diseases, particularly ischemic diseases, and this is considered to be an important clinical test item.
Nevertheless, in developed countries where various problems arise such as increased medical costs, etc., or in countries with small medical budgets, the increasing clinical test costs are posing another problem. The HDL-C measurement of the prior art requires cumbersome operations such as a centrifugal precipitation, etc., and has a relatively higher cost, and therefore, although clinically necessary, it is not often used.
For this reason, there is an urgent need ~or a rapid development of a simple, less expensive, and more accurate HDL-C measurement method.
DISCLOSURE OF THE INVENTION
Accordingly, an object of the present invention is to provide a column packing which solves the problems of the high specific lipoprotein and/or HDL cholesterol fractionation measurement column packing of the prior art as described above, and enables a simple, inexpen-sive and accurate fractionation measurement of a high specific gra~ity lipoprotein and/or HDL cholesterol.
Other objects and advantages of the present invention will be apparent from the following deScription.
Accorcling to the present invention, there is provided a column packing for a high specific gravity 2~2~8~3 protein and/or HDL cholesterol fractionation measure-ment, and comprising a porous calcium phosphate compound as the constituent.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention is now described with reference to the accompanying drawings, wherein:
Fig. l shows the selectivity of an adsorption of serum lipoproteins onto hydroxyapatite(HA); Fig. la showing the distribution of lipoproteins in an original serum, Fig. lb showing the distribution o~ lipoproteins in the supernatant in which 200 mg of ~A is added to original serum, Fig. lc showing the distribution of lipoproteins of a sample having a l/l0 amount of a phosphate buffer added to the original serllm, and Fig. ld showing the distribution of lipoproteins in the supernatant in which 200 mg of HA is added to the sample having a l/l0 amount of a phosphate buffer added to the original serum. In each Figure, the axis of the abscissa indicates the phoresis distance from the original point, and the axis of the ordinate shows the absorbance. In Fig. l, ~-Lipo is ~-lipoprotein and ~-Lipo is ~-lipoprotein, respectively.
Fig. 2 shows the constitution of the system of the present adsorption column, and is broadly classified into the pre-treatment block and the main column block.
Each block comprises a sample injection portion, a serum-phosphate ion mixing portion, a powder-serum contacting portion, a lipid selective adsorbent main body portion, a powder-serum separation portionr and a sample fractionated li~uid release portion. The fractionated liquid released is used for a pre-treatment during a cholesterol measurement in high specific gravity lipoproteins according to the chemical method, the enzymatic method, and the enzyme and/or antibody method (Dietschy JM, et al. Enzymatic measurement of free and esterified cholesterol levels in plasma and other biological preparations using the oxygen electrode 2~883 in a modified glucose analy~er. Clin Chim Acta, 73 (3) 407-417, 1976), the EIA method, the RIA method or the electrophoretic me~hod, measured by the manual method or by the automatic analytical method.
BEST MODE OF CARRYING OUT THE INVENTION
The present inventors made an intensive study of this matter, and consequently found that a calcium phosphate compound f particularly a synthetic hydroxy~
apatite used in a phosphate ion atmosphere selectively, adsorbs a low specific gravity lipoprotein and/or LDL-C, ultra-low specific gravity lipoprotein and/or VLDL-C, and a neutral fat or phospholipid, without an adsorption of a high specific gravity lipoprotein and/or ~DL-C, and thus developed a column packing for a high specific gravity lipoprotein and/or HDL-C fractionation measure-ment using this adsorbent.
The lipid adsorbent according to the present invention, and the column design, are described in detail as follows.
The components constituting the column packing for a high specific gravity lipoprotein fractionation measurement according to the present invention are a calcium phosphate compound and a phosphorus containing compound. Also, to improve the lipid adsorption selectivity, a fractionation characteristic potentiating agent can be added. As such a fractionation character-istic potentiating agent, for examplef there can be added sur~actants, fatty acids, divalent ion chelating agents such as EDTA, EGTA, polyanions such as heparin, dextran sulfate, amino acids, proteins, oligoproteins, saccharides, saccharide containing compounds, heavy metal salts, heavy metal salt-containing compounds, phosphotungstic acid, and poly~alent metal ions such as manganese ion, magnesium ion, and nickel ion (Tsuguhiko Nakai: HDL-metabolism, Measurement and clinic, Chugai Igakusha, p. 102 - 140, 1986).
For the adsorbent to be filled in the column, to 2~2~883 prevent a flowing out of the fine powder, a polyHEMA
coating treatment can be applied to the surface of the powder (literature: Matsuhiko Suenaga et al., Direct Hemoperfusion 12 with Petroleum Pitch Activated Charcoal, Investigated Artificial Organ of Clinical Example, Vol. 6, No. 6, p. 4~2 - 445, 1977), or the adsorbent can be filled in a column through a filter such as a MILLIPORE filter having a pore size of 0.45 ~m and manufactured by Millipore. The calcium phosphate compound to be used in the present invention can be made powdery or granular, but preferably, for example, a powder having a particle size of 0.01 ~m to 500 ~m is used. More preferably, the particle size is 80 ~m to 300 ~m, most preferably 150 ~m to 180 ~m. Also, a powder having spherical shaped particles formed by a spray drying method, and having a size as mentioned above, can be used.
The basic constitution of the column adsorbent for a high specific gravity lipoprotein fractionation measurement comprises an adsorbent composed of a calcium phosphate compound, a phosphoric acid atmosphere, and a lipid selective potentiating substance such as a metal anion or polyanion.
Examples of the calcium phosphate compound to be used in the present invention include synthetic hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, chlorine apatite, fluorine apatite, calcium phosphate type glass, or composites of these materials with other ceramics and/or glasses, those coated on the surface of metals or polymeric resins, and bone powder containing calcium phosphate.
As the phosphorus containing compound, for example, phosphates such as sodium phosphate and potassium phosphate, phosphoric acid, phosphate ion or phos-phorus-containing organic materials, and pyrophosphoric acid, can be specifically mentioned. Alternatively, ~29883 polyanions such as an arsenic-containing compound, heparin or dextran sulfate can be exemplified.
As the divalent ion chelating agent which can be used in the present invention, EDTA and EGT~ can be exemplified, but citric acid, which is a chelating agent of, for example, calcium, can be also used.
To impart a selective lipid adsorption function of making HDL-C non-adsorptive to a calcium phosphate compound, the calcium phosphate compound must be in a phosphate ion atmosphere, and accordingly, an inorganic acid such as hydrochloric acid and sulfuric acid or an organic acid such as citric acid, succinic acid, lactic acid, and acetic acid, capable of liberating phosphate ions from the calcium phosphate compound, can be used as the constituent, and further, a substance having a material containing a calcium phosphate compound and/or a calcium phosphate compound treated with the inorganic acid, and the organic acid as mentioned above, can be also used in the present invention.
The calcium phosphate compound which can be used in the present invention, as described above, can be a synthetic hydroxyapatite, natural hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, chlorine apatite, and fluorine apatite, but among them, synthetic hydroxyapatite has an excellent lipid selectivity and adsorption ability.
Also, calcium phosphate with a molar ratio of calcium to phosphorus (Ca/P) of 1 to 2, more preferably 1.5 to 1.7, is preferably used. To improve the adsorption charac-teristics of the lipid adsorbent, dried powder pulverized by a sample mill or a jet mill, or powder prepared by a calcination at a temperature of 60C to 1300C is preferably used. Particularly, a powder prepared by calcination at 300C to 1200C, more preferably 400C to 800C, is preferably used.
The block constitution of the adsorption system according to the present invention, as shown in Fig. 2, 2~29~3 comprises a sample injection portion, a serum-selective potentiating substance mixing portion, a powder-serum contact portion, a lipid selective adsorbent main body, a powder-serum separation portion, and a sample fractionated liquid release portion.
As the column material, polymeric resins such as polypropylene, TPX, acryl, polycarbonate, silicone rubber, and Teflon, and polyurethane and segment polyurethane, which are anti-thrombus materials for medical use, may be exemplified. Also, glass, ceramics, and metal can ~e used. For the sample injection portion and the fractionated liquid release portion, for example, the inserting system, the packing system or the one touch lock system can be used.
The lipid adsorbent which can be used in the present invPntion may be formed, for example, from the adsorbent carrier as described above and phosphate ions and/or a lipid precipitating substance.
A simple system column can be constituted of (1) the injection cylinder connecting portion, (2) the lipid adsorbent main column portion, and (3) the fractionated liquid release portion.
Examples Examples are now given which show the character-istics of the lipid adsorbent and HDL-C measurement according to the present invention, but the present invention is not limited to these Examples.
Experimental Example 1 A hydroxyapatite (HA) with a Ca/P molar ratio of 1.66 and synthesized by the wet process was pulverized by an attrition mill and calcined at 800C to obtain a powder.
To 1 ml of human serum or 1 ml of a sample having lO0 ml of a 0.5 M phosphate buffer (pH 7.4~ added thereto, to make the whole volume to l.l ml, was added 200 mg of HA, and after the mixture was gently stirred at room temperature for 10 minutes, the centrifuged 2~2~883 supernatant was subjected to an analysis of the distribution of the lipoprotein by using a Corning Universal Silum reagent and Helena densitometer.
The results are shown in Fig. l; wherein Fig. la shows the distribution of li.poproteins in the original serum, and Fig. lb the distribution of lipoproteins in the supernatant in which 200 mg of HA was added to original serum. Figure lc shows the distribution of lipoproteins of the sample having a l/lO amount of phosphate buffer added to the original serum, and Fig. ld shows the distribution of lipoproteins in the supernatant in which 200 mg of HA was added to the sample having a l/lO amount of phosphate buffer added to the original serum.
From the results in Fig. ld, it can be understood that, although ~-lipoproteins are absorbed, the ~-lipo-proteins are non-adsorptive. The characteristic shown in Fig. ld is that of the selectivity of lipoproteins of the adsorbent according to the present invention.
The homology between the ~-lipoprotein and HDL-C, and the homology between the ~-lipoprotein and LDL-C, is widely known.
Experimental Example 2 To determine the relationship between the total cholesterol value ( TCHO) and the HDL cholesterol value (HDL-C), and the relationship to the HA amount, to lO00 ~l of a sample supplemented with a phosphate buffer were added, respectively, lO0 mg, 200 mg, 300 mg, and 400 mg of the HA used in Experimental Example 1, and the mixture was gently stirred at room temperature for lO
minutes. Then, the TCHO value and HDL-C value in the centrifuged supernatant were measured by the enzymatic method. For the measurement of TCHO, a cholesterol measurement kit C II manufactured by Wako Junyaku was used, and 200 mg/dl of the standard manufactured by Kyowa Medics was employed (sample amount lO ~l). For the measurement of HDL-C, a pre-treatment was conducted 2~2~83 by a Determiner HDL kit manufactured by Kyowa Medics, and the measurement conducted by using a cholesterol measurement kit C II manufactured by Wako Junyaku. As the standard, 50 my/dl of one manufactured by Kyowa S Medics was employed (sample amount 50 ~1). The measure-ment was conducted by a spectrophotometer Ultraspec II
manufactured by Pharm~cia-LI~B.
The results are shown Ln Table 1.
Table 1 TCHO tmg/dl) HDLC ~mg/dl) Case 1 1. Original serum 431 52 2. 1 + 1/10 PB372 49 3. 2 + 100 mgHA176 50 4. 2 + 200 mgHA57 48 5. 2 ~ 300 mgHA45 46 6. 2 + 400 mgHA41 42 Case 2 1. Original serum 152 22 2. 1 + 1/10 PB134 20 3. 2 + 100 mg~A41 21 4. 2 + 200 mgHA24 21 5. 2 + 300 mgHA20 21 6. 2 + 400 mgHA19 20 Case 3 1. Original serum 65 21 2. 1 + 1¦10 PB 62 20 3. 2 + 100 mgEA21 21 4. 2 + 200 mgEA19 21 5. 2 + 300 mgHA20 20 6. 2 + 400 mgHA20 20 Case 4 1. Original serum 75 24 2. 1 + 1/10 PB 69 22 3. 2 + 100 mgEA19 22 4. 2 + 200 mgaA18 20 5. 2 + 300 mgEA17 19 6. 2 ~ 400 mgHA16 17 The addition of 300 mg of HA ma~es the TCHO value substantially the same as the HDL-C value in all of the respective cases.
Experimental Example 3 lo- 2~29883 To determine the total cholesterol ~alue (TCHO), the HDL cholesterol value (HDL-C), and the lipid adsorp-tion with HA, a simultaneous mèasurement by the enzymatic method was carriecl out. For the adsorption of HA, 500 ~1 of a phosphate buffer was added to 500 ~1 of a serum sample, and then 150 mg of HA used in Experi-mental Example 1 was added thereto. After slowly stirring at room temperature for 10 minutes, the TCHO
value in the centrifuged supernatant was measured by the anzymatic method. For the measurement of HDL-C, 100 ~1 of a Determiner HDL precipitation reagent manufactured by Kyowa Medics was added to 200 ~1 of a serum sample, and after stirring, the mixture was left to stand for 10 minutes, followed by a measurement of the TCHO value in the centrifuged supernatant by the enzymatic method.
For the measurement of TCHO, a cholesterol measurement kit C II manufactured by Wako Junyaku was used. For the standard, 50 mg/dl of one manufactured by Kyowa Medics was used (sample amount 50 ~1). The measurement was carried out by a spectrophotometer Ultraspec II manufac-tured by Pharmacia-LKB.
The results are shown in Table 2.
Table 2 TCHO (mg/dl) HA (mg/dl) HDL-C (mg/dl) Case 5 237 49 48 Case 6 251 61 62 . _ _ The TCHO concentration of the sample adsorbed with 150 mg of HA is substantially the same as the HDL-C
concentration.
As apparent from the respective Examples as described above, the column using the column packing for a hi~h specific gravity lipoprotein fractionation 2~2~8~3 measurement according to the present invention can fractionate HDL-C in the serum without performing the precipitation and centrifugation operations. Also, the present column can be used not only merely as a pre-column which prepares fractionation samples to be measured by the manual method or the auiomatic analytical instrument, but also in the construction of an automated HDL-C measurement system assembled within an automatic analyzer, for example.
- 1 2~29~83 DESCRIPTION
TITLE OF THE INVENTION
Column Packing for High Specific Gravity Lipoprotein and/or HDL Cholesterol Fractionation Measurement TECHNICAL FIELD
This invention relates to a column packing (or filler~ for high specific gravity lipoprotein and~or HDL
cholesterol fractionation measurement.
BACKGROUND ART
The recent trend in Japan toward the adoption of a western diet has led to the opening of a large number of supermarkets after midnight supplying a vast diYersity of food, etc. Also, a gourmet boom has led to an intake of foods having a higher calory content. Accordingly, the growth of diseases caused by over-eating, etc., such as diabetes, hyperlipemia or fatty liver, has increased, and accordingl~, it appears to be time to cut down on the intake of many foods. On the other hand, from a global point of view, in many developping countries and countries in a state of war, due to an extremely poor hygienic environment or to a severe lack of food, there are many people who are suffering from an irreversible malnutrition. The therapy of the diseases due to nutritional disorders caused by such an excessive or insufficient nutrition mer~ly by negative methods, such as a nutritional limitation or supplementation, etc., does not always give good results, and accordingly, in most practical clinics, a large number of therapeutical methods, including a drug therapy such as the hyperlipemia therapeutic method, the plasma exchange-plasma separation method, and the central vein nutrition method, etc., have been investigated.
Also, simultaneously with the establishment o~ the therapeutical method, due to the progress made in 3s clinical tests in the diagnosis field, such as the 2029~83 advent of the en~ymatic method and development of a biological automatic analyzer, the tested number of lipids in blood has increased, and further, a precise diagnosis, such as an apoprotein measurement, is now possible, and the significance thereof in clinical tests is increasing. The measurement of high specific gravity lipoprotein and/or HDL cholesterol (HDL-C) fractions has become substantially routine among the series of lipid tests. This is because it is widely known that there is a negative correlation between the HDL-C concentration and the onset ratio of arterioscrelotic diseases, particularly ischemic diseases, and this is considered to be an important clinical test item.
Nevertheless, in developed countries where various problems arise such as increased medical costs, etc., or in countries with small medical budgets, the increasing clinical test costs are posing another problem. The HDL-C measurement of the prior art requires cumbersome operations such as a centrifugal precipitation, etc., and has a relatively higher cost, and therefore, although clinically necessary, it is not often used.
For this reason, there is an urgent need ~or a rapid development of a simple, less expensive, and more accurate HDL-C measurement method.
DISCLOSURE OF THE INVENTION
Accordingly, an object of the present invention is to provide a column packing which solves the problems of the high specific lipoprotein and/or HDL cholesterol fractionation measurement column packing of the prior art as described above, and enables a simple, inexpen-sive and accurate fractionation measurement of a high specific gra~ity lipoprotein and/or HDL cholesterol.
Other objects and advantages of the present invention will be apparent from the following deScription.
Accorcling to the present invention, there is provided a column packing for a high specific gravity 2~2~8~3 protein and/or HDL cholesterol fractionation measure-ment, and comprising a porous calcium phosphate compound as the constituent.
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention is now described with reference to the accompanying drawings, wherein:
Fig. l shows the selectivity of an adsorption of serum lipoproteins onto hydroxyapatite(HA); Fig. la showing the distribution of lipoproteins in an original serum, Fig. lb showing the distribution o~ lipoproteins in the supernatant in which 200 mg of ~A is added to original serum, Fig. lc showing the distribution of lipoproteins of a sample having a l/l0 amount of a phosphate buffer added to the original serllm, and Fig. ld showing the distribution of lipoproteins in the supernatant in which 200 mg of HA is added to the sample having a l/l0 amount of a phosphate buffer added to the original serum. In each Figure, the axis of the abscissa indicates the phoresis distance from the original point, and the axis of the ordinate shows the absorbance. In Fig. l, ~-Lipo is ~-lipoprotein and ~-Lipo is ~-lipoprotein, respectively.
Fig. 2 shows the constitution of the system of the present adsorption column, and is broadly classified into the pre-treatment block and the main column block.
Each block comprises a sample injection portion, a serum-phosphate ion mixing portion, a powder-serum contacting portion, a lipid selective adsorbent main body portion, a powder-serum separation portionr and a sample fractionated li~uid release portion. The fractionated liquid released is used for a pre-treatment during a cholesterol measurement in high specific gravity lipoproteins according to the chemical method, the enzymatic method, and the enzyme and/or antibody method (Dietschy JM, et al. Enzymatic measurement of free and esterified cholesterol levels in plasma and other biological preparations using the oxygen electrode 2~883 in a modified glucose analy~er. Clin Chim Acta, 73 (3) 407-417, 1976), the EIA method, the RIA method or the electrophoretic me~hod, measured by the manual method or by the automatic analytical method.
BEST MODE OF CARRYING OUT THE INVENTION
The present inventors made an intensive study of this matter, and consequently found that a calcium phosphate compound f particularly a synthetic hydroxy~
apatite used in a phosphate ion atmosphere selectively, adsorbs a low specific gravity lipoprotein and/or LDL-C, ultra-low specific gravity lipoprotein and/or VLDL-C, and a neutral fat or phospholipid, without an adsorption of a high specific gravity lipoprotein and/or ~DL-C, and thus developed a column packing for a high specific gravity lipoprotein and/or HDL-C fractionation measure-ment using this adsorbent.
The lipid adsorbent according to the present invention, and the column design, are described in detail as follows.
The components constituting the column packing for a high specific gravity lipoprotein fractionation measurement according to the present invention are a calcium phosphate compound and a phosphorus containing compound. Also, to improve the lipid adsorption selectivity, a fractionation characteristic potentiating agent can be added. As such a fractionation character-istic potentiating agent, for examplef there can be added sur~actants, fatty acids, divalent ion chelating agents such as EDTA, EGTA, polyanions such as heparin, dextran sulfate, amino acids, proteins, oligoproteins, saccharides, saccharide containing compounds, heavy metal salts, heavy metal salt-containing compounds, phosphotungstic acid, and poly~alent metal ions such as manganese ion, magnesium ion, and nickel ion (Tsuguhiko Nakai: HDL-metabolism, Measurement and clinic, Chugai Igakusha, p. 102 - 140, 1986).
For the adsorbent to be filled in the column, to 2~2~883 prevent a flowing out of the fine powder, a polyHEMA
coating treatment can be applied to the surface of the powder (literature: Matsuhiko Suenaga et al., Direct Hemoperfusion 12 with Petroleum Pitch Activated Charcoal, Investigated Artificial Organ of Clinical Example, Vol. 6, No. 6, p. 4~2 - 445, 1977), or the adsorbent can be filled in a column through a filter such as a MILLIPORE filter having a pore size of 0.45 ~m and manufactured by Millipore. The calcium phosphate compound to be used in the present invention can be made powdery or granular, but preferably, for example, a powder having a particle size of 0.01 ~m to 500 ~m is used. More preferably, the particle size is 80 ~m to 300 ~m, most preferably 150 ~m to 180 ~m. Also, a powder having spherical shaped particles formed by a spray drying method, and having a size as mentioned above, can be used.
The basic constitution of the column adsorbent for a high specific gravity lipoprotein fractionation measurement comprises an adsorbent composed of a calcium phosphate compound, a phosphoric acid atmosphere, and a lipid selective potentiating substance such as a metal anion or polyanion.
Examples of the calcium phosphate compound to be used in the present invention include synthetic hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, chlorine apatite, fluorine apatite, calcium phosphate type glass, or composites of these materials with other ceramics and/or glasses, those coated on the surface of metals or polymeric resins, and bone powder containing calcium phosphate.
As the phosphorus containing compound, for example, phosphates such as sodium phosphate and potassium phosphate, phosphoric acid, phosphate ion or phos-phorus-containing organic materials, and pyrophosphoric acid, can be specifically mentioned. Alternatively, ~29883 polyanions such as an arsenic-containing compound, heparin or dextran sulfate can be exemplified.
As the divalent ion chelating agent which can be used in the present invention, EDTA and EGT~ can be exemplified, but citric acid, which is a chelating agent of, for example, calcium, can be also used.
To impart a selective lipid adsorption function of making HDL-C non-adsorptive to a calcium phosphate compound, the calcium phosphate compound must be in a phosphate ion atmosphere, and accordingly, an inorganic acid such as hydrochloric acid and sulfuric acid or an organic acid such as citric acid, succinic acid, lactic acid, and acetic acid, capable of liberating phosphate ions from the calcium phosphate compound, can be used as the constituent, and further, a substance having a material containing a calcium phosphate compound and/or a calcium phosphate compound treated with the inorganic acid, and the organic acid as mentioned above, can be also used in the present invention.
The calcium phosphate compound which can be used in the present invention, as described above, can be a synthetic hydroxyapatite, natural hydroxyapatite, tricalcium phosphate, tetracalcium phosphate, calcium pyrophosphate, chlorine apatite, and fluorine apatite, but among them, synthetic hydroxyapatite has an excellent lipid selectivity and adsorption ability.
Also, calcium phosphate with a molar ratio of calcium to phosphorus (Ca/P) of 1 to 2, more preferably 1.5 to 1.7, is preferably used. To improve the adsorption charac-teristics of the lipid adsorbent, dried powder pulverized by a sample mill or a jet mill, or powder prepared by a calcination at a temperature of 60C to 1300C is preferably used. Particularly, a powder prepared by calcination at 300C to 1200C, more preferably 400C to 800C, is preferably used.
The block constitution of the adsorption system according to the present invention, as shown in Fig. 2, 2~29~3 comprises a sample injection portion, a serum-selective potentiating substance mixing portion, a powder-serum contact portion, a lipid selective adsorbent main body, a powder-serum separation portion, and a sample fractionated liquid release portion.
As the column material, polymeric resins such as polypropylene, TPX, acryl, polycarbonate, silicone rubber, and Teflon, and polyurethane and segment polyurethane, which are anti-thrombus materials for medical use, may be exemplified. Also, glass, ceramics, and metal can ~e used. For the sample injection portion and the fractionated liquid release portion, for example, the inserting system, the packing system or the one touch lock system can be used.
The lipid adsorbent which can be used in the present invPntion may be formed, for example, from the adsorbent carrier as described above and phosphate ions and/or a lipid precipitating substance.
A simple system column can be constituted of (1) the injection cylinder connecting portion, (2) the lipid adsorbent main column portion, and (3) the fractionated liquid release portion.
Examples Examples are now given which show the character-istics of the lipid adsorbent and HDL-C measurement according to the present invention, but the present invention is not limited to these Examples.
Experimental Example 1 A hydroxyapatite (HA) with a Ca/P molar ratio of 1.66 and synthesized by the wet process was pulverized by an attrition mill and calcined at 800C to obtain a powder.
To 1 ml of human serum or 1 ml of a sample having lO0 ml of a 0.5 M phosphate buffer (pH 7.4~ added thereto, to make the whole volume to l.l ml, was added 200 mg of HA, and after the mixture was gently stirred at room temperature for 10 minutes, the centrifuged 2~2~883 supernatant was subjected to an analysis of the distribution of the lipoprotein by using a Corning Universal Silum reagent and Helena densitometer.
The results are shown in Fig. l; wherein Fig. la shows the distribution of li.poproteins in the original serum, and Fig. lb the distribution of lipoproteins in the supernatant in which 200 mg of HA was added to original serum. Figure lc shows the distribution of lipoproteins of the sample having a l/lO amount of phosphate buffer added to the original serum, and Fig. ld shows the distribution of lipoproteins in the supernatant in which 200 mg of HA was added to the sample having a l/lO amount of phosphate buffer added to the original serum.
From the results in Fig. ld, it can be understood that, although ~-lipoproteins are absorbed, the ~-lipo-proteins are non-adsorptive. The characteristic shown in Fig. ld is that of the selectivity of lipoproteins of the adsorbent according to the present invention.
The homology between the ~-lipoprotein and HDL-C, and the homology between the ~-lipoprotein and LDL-C, is widely known.
Experimental Example 2 To determine the relationship between the total cholesterol value ( TCHO) and the HDL cholesterol value (HDL-C), and the relationship to the HA amount, to lO00 ~l of a sample supplemented with a phosphate buffer were added, respectively, lO0 mg, 200 mg, 300 mg, and 400 mg of the HA used in Experimental Example 1, and the mixture was gently stirred at room temperature for lO
minutes. Then, the TCHO value and HDL-C value in the centrifuged supernatant were measured by the enzymatic method. For the measurement of TCHO, a cholesterol measurement kit C II manufactured by Wako Junyaku was used, and 200 mg/dl of the standard manufactured by Kyowa Medics was employed (sample amount lO ~l). For the measurement of HDL-C, a pre-treatment was conducted 2~2~83 by a Determiner HDL kit manufactured by Kyowa Medics, and the measurement conducted by using a cholesterol measurement kit C II manufactured by Wako Junyaku. As the standard, 50 my/dl of one manufactured by Kyowa S Medics was employed (sample amount 50 ~1). The measure-ment was conducted by a spectrophotometer Ultraspec II
manufactured by Pharm~cia-LI~B.
The results are shown Ln Table 1.
Table 1 TCHO tmg/dl) HDLC ~mg/dl) Case 1 1. Original serum 431 52 2. 1 + 1/10 PB372 49 3. 2 + 100 mgHA176 50 4. 2 + 200 mgHA57 48 5. 2 ~ 300 mgHA45 46 6. 2 + 400 mgHA41 42 Case 2 1. Original serum 152 22 2. 1 + 1/10 PB134 20 3. 2 + 100 mg~A41 21 4. 2 + 200 mgHA24 21 5. 2 + 300 mgHA20 21 6. 2 + 400 mgHA19 20 Case 3 1. Original serum 65 21 2. 1 + 1¦10 PB 62 20 3. 2 + 100 mgEA21 21 4. 2 + 200 mgEA19 21 5. 2 + 300 mgHA20 20 6. 2 + 400 mgHA20 20 Case 4 1. Original serum 75 24 2. 1 + 1/10 PB 69 22 3. 2 + 100 mgEA19 22 4. 2 + 200 mgaA18 20 5. 2 + 300 mgEA17 19 6. 2 ~ 400 mgHA16 17 The addition of 300 mg of HA ma~es the TCHO value substantially the same as the HDL-C value in all of the respective cases.
Experimental Example 3 lo- 2~29883 To determine the total cholesterol ~alue (TCHO), the HDL cholesterol value (HDL-C), and the lipid adsorp-tion with HA, a simultaneous mèasurement by the enzymatic method was carriecl out. For the adsorption of HA, 500 ~1 of a phosphate buffer was added to 500 ~1 of a serum sample, and then 150 mg of HA used in Experi-mental Example 1 was added thereto. After slowly stirring at room temperature for 10 minutes, the TCHO
value in the centrifuged supernatant was measured by the anzymatic method. For the measurement of HDL-C, 100 ~1 of a Determiner HDL precipitation reagent manufactured by Kyowa Medics was added to 200 ~1 of a serum sample, and after stirring, the mixture was left to stand for 10 minutes, followed by a measurement of the TCHO value in the centrifuged supernatant by the enzymatic method.
For the measurement of TCHO, a cholesterol measurement kit C II manufactured by Wako Junyaku was used. For the standard, 50 mg/dl of one manufactured by Kyowa Medics was used (sample amount 50 ~1). The measurement was carried out by a spectrophotometer Ultraspec II manufac-tured by Pharmacia-LKB.
The results are shown in Table 2.
Table 2 TCHO (mg/dl) HA (mg/dl) HDL-C (mg/dl) Case 5 237 49 48 Case 6 251 61 62 . _ _ The TCHO concentration of the sample adsorbed with 150 mg of HA is substantially the same as the HDL-C
concentration.
As apparent from the respective Examples as described above, the column using the column packing for a hi~h specific gravity lipoprotein fractionation 2~2~8~3 measurement according to the present invention can fractionate HDL-C in the serum without performing the precipitation and centrifugation operations. Also, the present column can be used not only merely as a pre-column which prepares fractionation samples to be measured by the manual method or the auiomatic analytical instrument, but also in the construction of an automated HDL-C measurement system assembled within an automatic analyzer, for example.
Claims (7)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A column packing for a high specific gravity lipoprotein and/or HDL cholesterol fractionation measurement and comprising a porous calcium phosphate compound as the constituent.
2. A column packing according to claim 1, wherein the porous calcium phosphate compound is a powdery and/or granular calcium phosphate compound.
3. A column packing according to claim 1 or 2, containing at least one fractionation characteristic potentiator shown below which potentiates a high specific gravity lipoprotein and/or HDL cholesterol fractionation characteristic:
a) phosphorus-containing compound b) surfactant c) fatty acid d) polyanion e) amino acid f) protein and/or glycoprotein g) saccharide and/or saccharide-con-taining compound h) heavy metal salt and/or heavy metal-containing compound i) polyvalent cation.
a) phosphorus-containing compound b) surfactant c) fatty acid d) polyanion e) amino acid f) protein and/or glycoprotein g) saccharide and/or saccharide-con-taining compound h) heavy metal salt and/or heavy metal-containing compound i) polyvalent cation.
4. A column packing according to claim 1, 2, or 3 wherein the column packing for a high specific gravity lipoprotein and/or HDL cholesterol fractionation measurement adsorbs low specific gravity protein and/or LDL cholesterol and/or ultra-low specific gravity lipoprotein and/or VLDL cholesterol.
5. A column packing according to claim 1, 2 or 3 wherein the column packing for a high specific gravity lipoprotein and/or HDL cholesterol fractionation measurement does not adsorb a high specific gravity lipoprotein and/or cholesterol.
6. A column packing according to claim 1, 2, 3, 4 or 5, wherein said adsorption column is used for a pre-treatment, and is used for the manual method or the automatic analytical method of cholesterol (HDL-C) measurement in a high specific gravity lipoprotein according to the chemical method, the enzymatic method, enzyme and/or antibody electrode method, the EIA method RIA method or the electrophoretic method.
7. A column packing according to claim 1, wherein said porous calcium phosphate compound has a Ca/P molar ratio of 1 to 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002029883A CA2029883A1 (en) | 1990-04-06 | 1990-04-06 | Column packing for high specific gravity liporotein and/or hdl cholesterol fractionation measurement |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002029883A CA2029883A1 (en) | 1990-04-06 | 1990-04-06 | Column packing for high specific gravity liporotein and/or hdl cholesterol fractionation measurement |
| PCT/JP1990/000468 WO1991015760A1 (en) | 1988-10-07 | 1990-04-06 | Packing of column for fractionating and assaying high specific gravity lipoprotein and/or hdl cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2029883A1 true CA2029883A1 (en) | 1991-10-07 |
Family
ID=25674369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002029883A Abandoned CA2029883A1 (en) | 1990-04-06 | 1990-04-06 | Column packing for high specific gravity liporotein and/or hdl cholesterol fractionation measurement |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2029883A1 (en) |
-
1990
- 1990-04-06 CA CA002029883A patent/CA2029883A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McMENAMY et al. | Unbound amino acid concentrations in human blood plasmas | |
| Weller et al. | Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals. | |
| Holmouist et al. | Comparison between the use of isopropanol and tetramethylurea for the solubilisation and quantitation of human serum very low density apollpoproteins | |
| EP0031955B1 (en) | Process for purification of lipoprotein cholesterol for use as a cholesterol reference material | |
| US4045176A (en) | Preparation of optically clear serum | |
| Hara et al. | Rapid analysis of cholesterol of high density lipoprotein and low density lipoprotein in human serum by high performance liquid chromatography | |
| CA1327674C (en) | Method and apparatus for separating proteins | |
| Sanui et al. | Sodium and potassium binding by rat liver cell microsomes | |
| Berry | Paper chromatographic method for estimation of phenylalanine. | |
| Becker et al. | Determination of the binding of 2, 4, 5, 2’, 4’, 5'‐hexachlorobiphenyl by low density lipoprotein and bovine serum albumin | |
| EP0283779B1 (en) | Method of assaying high molecular hyaluronic acid | |
| Vu et al. | New assay for the rapid determination of plasma holotranscobalamin II levels: preliminary evaluation in cancer patients | |
| AU633314B2 (en) | Packing of column for fractionating and assaying high specific gravity lipoprotein and/or hdl cholesterol | |
| Schwarz et al. | Phospholipid composition of blood plasma, erythrocytes, and" ghosts" in sickle cell disease. | |
| CA2145389A1 (en) | Quantitative measurement of ldl | |
| CA2029883A1 (en) | Column packing for high specific gravity liporotein and/or hdl cholesterol fractionation measurement | |
| JPH0220068B2 (en) | ||
| WO1984000689A1 (en) | Extraction of bound toxins from the blood | |
| Statland et al. | Variations of cholesterol and total lipid concentrations in sera of healthy young men: differentiating analytic error from biologic variability | |
| Karai et al. | Alterations of lipids of the erythrocyte membranes in workers exposed to lead | |
| Moorjani et al. | Extracorporeal removal of plasma lipoproteins by affinity binding to heparin-agarose | |
| Kahlenberg et al. | d-Glucose Uptake by Isolated Human Erythrocyte Membranes versusd-Glucose Transport by Human Erythrocytes: COMPARISON OF THE EFFECTS OF PROTEOLYTIC AND PHOSPHOLIPASE A2 DIGESTION | |
| US4158547A (en) | Method of separating components in a biological fluid | |
| Moo‐Penn et al. | Hemoglobin Connecticut (β21 (B3) Asp→ Gly): A hemoglobin variant with low oxygen affinity | |
| Hürter et al. | Phospholipids of red cells and blood plasma in adults, newborn infants, and patients with Rh erythroblastosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |